Springer Nature AG & Co. KGaA/€SPG

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Springer Nature AG & Co. KGaA

Springer Nature AG & Co. KGaA is a global academic publishing company specializing in research, health, and educational content. Formed in 2015 through the merger of Springer Science+Business Media and Holtzbrinck Publishing Group's Nature Publishing Group, Palgrave Macmillan, and Macmillan Education, the company publishes a wide array of scientific, technical, and medical journals under the Nature and Springer brands, as well as books and e-books across various disciplines. Headquartered in Berlin, Germany, with additional offices in London and New York City, Springer Nature operates in over 40 countries worldwide. The company has a significant presence in open access publishing, with 50% of its primary research articles published as open access in 2024, and continues to invest in technology and AI to enhance the publishing process. (,)

Ticker

€SPG

Sector

Communication

Primary listing

XETRA

Employees

9,136

SPG Metrics

BasicAdvanced
€4.6B
-
-
-
€0.13
0.56%

Bulls say / Bears say

Springer Nature projects 2025 revenue in the range of €1.89 billion to €1.94 billion, fueled by reaching 50% of primary research articles published as open access and backed by €177 million invested in technology and AI, while net debt has been reduced to 2.5 times EBITDA (Reuters)
In the first half of 2025, underlying revenue climbed 6% to €926 million and adjusted operating profit jumped 10% to €241 million. This strong performance led to upgraded full-year guidance of €1.93–€1.96 billion in revenue and €540–€560 million in adjusted operating profit (Reuters)
CEO Frank Vrancken Peeters highlighted the achievement of publishing 50% of primary research output as open access and reaffirmed the goal of hitting 75% within the next three years, underlining Springer Nature’s leadership in the transition to open access (Reuters)
Despite efforts to cut debt, Springer Nature's net debt stands at 2.5 times EBITDA, which is above its target range of 1.5–2.0 and may constrain future strategic investments (Reuters)
Springer Nature’s move to open access—where publishing fees are paid by authors or their funders—creates exposure to risks from research funding cuts and increasing pressure to waive article processing charges, which could weigh on future revenue growth (Reuters)
Shares in Springer Nature are down roughly 25% year-to-date, showing that investor confidence remains weak, even as the company upgrades its guidance and improves operations (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SPG

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs
Buy Springer Nature AG & Co. KGaA stock | €SPG Share Price | Lightyear